# Phase 2 Opioid-Related Disorders trials: 28 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 28 trials in phase 2 for Opioid-Related Disorders that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Opioid-Related Disorders trials: 28 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/opioid-related-disorders

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 28
- Recruiting or not yet: 28
- Read on: November 19, 2026

## Trials

The 25 newest of 28, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 15, 2026 | NCT07874620 | A Study of Cebranopadol for Opioid Withdrawal Symptoms in Adults With Chronic Pain | Adneuris Therapeutics, Inc. | Phase 2 | Recruiting | Chronic Pain, Pain, Opioid Withdrawal (Disorder), Opioid Use Disorder | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07874620) |
| February 19, 2026 | NCT07420283 | A Study of Brenipatide in Participants With Opioid Use Disorder | Eli Lilly and Company | Phase 2 | Recruiting | Opioid Use Disorder | 465 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07420283) |
| January 27, 2026 | NCT07369089 | Targeting Treatment-Resistant OUD With Ketamine-Assisted Mindfulness Oriented Recovery Enhancement | University of California, San Diego | Phase 2 | Recruiting | Opioid Use Disorder | 88 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07369089) |
| December 19, 2025 | NCT07294118 | Infusion of Lidocaine and Steroids in Middle Meningeal Artery for Pain in Subarachnoid Hemorrhage | The University of Texas Medical Branch, Galveston | Phase 2 | Recruiting | Subarachnoid Hemorrhage, Aneurysmal, Headache, Opiate Dependence, Opioid Use | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07294118) |
| August 19, 2025 | NCT07128524 | Ketones for Opioid Craving | University of Maryland, Baltimore | Phase 2 | Recruiting | Opioid Use Disorder | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07128524) |
| June 10, 2025 | NCT07011758 | Dynamic Treatment Regimes for Opioid Use Disorder | Brigham and Women's Hospital | Phase 2 | Not yet recruiting | Opioid Use Disorder | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07011758) |
| May 20, 2025 | NCT06981195 | Effects of Lemborexant on Insomnia and Its Relationship to Mood and Behavior on Opioid Use Disorder Subjects | Virginia Commonwealth University | Phase 2 | Recruiting | Opioid Use Disorder, Opioid Use, Insomnia, Orexin Antagonist | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06981195) |
| April 24, 2025 | NCT06943859 | Ketamine for Opioid Use Disorder | University of Maryland, Baltimore | Phase 2 | Recruiting | Opioid Use Disorder | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06943859) |
| February 5, 2025 | NCT06810310 | Psilocybin on Brain Mechanisms of Motivation in OUD | University of Pennsylvania | Phase 2 | Recruiting | Opioid Use Disorder | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06810310) |
| January 28, 2025 | NCT06796062 | Psilocybin for Opioid Use Disorder (OUD) | NYU Langone Health | Phase 2 | Recruiting | Opioid Use Disorder | 480 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06796062) |
| October 21, 2024 | NCT06651177 | Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder | Sponsor not shown (see the record) | Phase 2 | Recruiting | Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe | 310 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06651177) |
| October 15, 2024 | NCT06639464 | Semaglutide for Helping Opioid Recovery | Brigham and Women's Hospital | Phase 2 | Recruiting | Opioid Use Disorder | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06639464) |
| September 23, 2024 | NCT06608459 | PEX010-Assisted Therapy for Opioid Use Disorder (OUD): a Feasibility Study | Filament Health Corp. | Phase 2 | Not yet recruiting | Opioid Use Disorder | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06608459) |
| August 12, 2024 | NCT06548490 | GLP-1R Agonist Treatment for Opioid Use Disorder | Milton S. Hershey Medical Center | Phase 2 | Recruiting | Opioid Use Disorder, Opioid Abuse and Addiction, Narcotic-Related Disorders, Substance-Related Disorders... | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06548490) |
| August 9, 2024 | NCT06544291 | Combined THC and CBD for OUD and Chronic Pain | Yale University | Phase 2 | Recruiting | Chronic Pain, Opioid Use Disorder | 147 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06544291) |
| July 26, 2024 | NCT06521476 | Acetazolamide in Central Sleep Apnea Patients Using Medication for Opioid Use Disorder | Sponsor not shown (see the record) | Phase 2 | Recruiting | Central Sleep Apnea Comorbid With Opioid Use | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06521476) |
| April 23, 2024 | NCT06379984 | Rapid Outpatient Low-dose Initiation of Buprenorphine for OUD With Fentanyl Use | University of Pennsylvania | Phase 2 | Recruiting | Opioid Use Disorder | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06379984) |
| March 29, 2024 | NCT06338280 | Remotely Observed Methadone Evaluation II | Sonara Health | Phase 2 | Recruiting | Opioid Use Disorder | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06338280) |
| October 5, 2023 | NCT06067737 | Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder | Johns Hopkins University | Phase 2 | Recruiting | Opioid Use Disorder | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06067737) |
| August 14, 2023 | NCT05985850 | Evaluating Tetrahydrocannabinol as an Adjunct to Opioid Agonist Therapy | BC Centre on Substance Use | Phase 2 | Recruiting | Opioid Use Disorder, Methadone, Cannabis, Fentanyl | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05985850) |
| February 10, 2023 | NCT05722561 | E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder | NYU Langone Health | Phase 2 | Recruiting | Opioid Use Disorder, Cigarette Smoking | 302 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05722561) |
| October 18, 2022 | NCT05585229 | Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication | University of British Columbia | Phase 2 | Recruiting | Opioid Dependence, Chronic Pain | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05585229) |
| September 7, 2022 | NCT05529927 | Efficacy and Safety of Sustained-release Dexamphetamine in Patients With Moderate to Severe Cocaine Use Disorder | Parnassia Addiction Research Centre | Phase 2 | Recruiting | Cocaine Use Disorder | 204 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05529927) |
| August 23, 2022 | NCT05511909 | Evaluating Buspirone to Treat Opioid Withdrawal | University of Maryland, Baltimore | Phase 2 | Recruiting | Opioid Use Disorder, Opioid Withdrawal, Opioid Craving, Anxiety | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05511909) |
| May 19, 2022 | NCT05382091 | Evaluation of the O'Neil Long Acting Naltrexone Implant in Opioid Dependent Persons | Go Medical Industries Pty Ltd | Phase 2 | Not yet recruiting | Opioid Use Disorder | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05382091) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| University of Maryland, Baltimore | 3 |
| Brigham and Women's Hospital | 2 |
| Wayne State University | 2 |
| NYU Langone Health | 2 |
| University of Pennsylvania | 2 |
| BC Centre on Substance Use | 1 |
| Sonara Health | 1 |
| University of New Mexico | 1 |
| Johns Hopkins University | 1 |
| Virginia Commonwealth University | 1 |
| Go Medical Industries Pty Ltd | 1 |
| Milton S. Hershey Medical Center | 1 |
| Parnassia Addiction Research Centre | 1 |
| University of California, San Diego | 1 |
| The University of Texas Medical Branch, Galveston | 1 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 1 |
| Adneuris Therapeutics, Inc. | 1 |
| University of British Columbia | 1 |
| Yale University | 1 |
| Filament Health Corp. | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 23 |
| Canada | 3 |
| Netherlands | 1 |
| Puerto Rico | 1 |
| United Kingdom | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Alternative medicine clinics in the United States](https://specstream.ai/data/businesses/alternative-medicine-clinics/united-states)
- [Medical law firms in the United States](https://specstream.ai/data/businesses/medical-law-firms/united-states)
- [Business schools in the United States](https://specstream.ai/data/businesses/business-schools/united-states)
- [Private jet charter companies in the United States](https://specstream.ai/data/businesses/private-jet-charter-companies/united-states)
- [Electrical wholesalers in the United States](https://specstream.ai/data/businesses/electrical-wholesalers/united-states)
- [Telecommunications services in the United States](https://specstream.ai/data/businesses/telecommunications-services/united-states)
